Oncology providers need sufficient resources to support an effective, efficient and healthy practice environment so that they can continue to provide high-quality, high-value care for their patients. ASCO has developed a series of policy statements that put forth recommendations on how to ensure oncology providers are adequately compensated for the services they provide and understand how to navigate changes as the healthcare delivery system transitions from fee-for-service to value-based care. ASCO’s policy statements on payment reform, as well as other reimbursement and coverage issues, reflect the complexities of cancer care and needs of practices and the patients they serve.
An important development in this area is the 2019 release of ASCO Patient-Centered Oncology Payment: A Community-Based Oncology Medical Home Model, a complete solution for transforming cancer care delivery and reimbursement while ensuring that all individuals with cancer have access to evidence-based cancer care.
ASCO policy statements provide commentary and analysis on important policy issues affecting the cancer community, including people with cancer and their cancer care teams. These statements are informed by volunteer leadership, who identify key policy issues and contribute to the development of ASCO’s policy positions.
Policy statements on coverage and reimbursement include:
- Telemedicine Cross-State Licensure (May 2021)
- Telemedicine in Cancer Care (July 2020)
- Patient-Centered Oncology Payment Reform (November 2015)
- Site-Neutral Payments in Oncology (November 2015)
- 340B Drug Pricing Program (April 2014)
- ASCO Survey Results: Sequestration's Impact on Oncology Practices (July 2013)
- Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications (February 2006)
ASCO also develops policy briefs, which are based on existing ASCO policy. These briefs provide additional content, key terms and definitions, and a more detailed look at a specific issue.
Policy briefs on reimbursement and coverage issues include:
- CAR T-cell Therapy (September 2020)